Evaluation and Clinical Application of Platelet Function Testing in Small Animal Practice

Veterinary Clinics of North America - Small Animal Practice

Volumn 42, Issue 1, 2012, Pages 173-188

  Christopherson, Pete W ^a   Spangler, Elizabeth A ^a   Boudreaux, Mary K ^a  

^a AUBURN UNIVERSITY   (United States)

Author keywords

Clot retraction; Platelet adhesion; Platelet aggregation; Platelet granule secretion; Primary hemostasis

Indexed keywords

ADENOSINE TRIPHOSPHATE; COLLAGEN BINDING PROTEIN; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; LIPOCORTIN 5; MEMBRANE PROTEIN; VON WILLEBRAND FACTOR;

AUTOANALYZER; BINDING SITE; BLEEDING TIME; BLOOD CLOT RETRACTION; BLOOD CLOTTING PARAMETERS; CLINICAL EVALUATION; CLINICAL PRACTICE; ELECTRON MICROSCOPY; FLOW CYTOMETRY; LIGAND BINDING; NONHUMAN; PROTEIN DETERMINATION; PROTEIN FUNCTION; RECEPTOR BINDING; REVIEW; SEROTONIN RELEASE; SEROTONIN UPTAKE; THROMBOCYTE FUNCTION; THROMBOELASTOGRAPHY;

ANIMALS; BLOOD PLATELET DISORDERS; CAT DISEASES; CATS; DOG DISEASES; DOGS; FLOW CYTOMETRY; PLATELET AGGREGATION; PLATELET COUNT; PLATELET FUNCTION TESTS;

ANIMALIA;

EID: 84856245834     PISSN: 01955616     EISSN: 18781306     Source Type: Journal    
DOI: 10.1016/j.cvsm.2011.09.013     Document Type: Review

References (67)

1. Jergens A.E., Turrentine M.A., Kraus K.H., et al. Buccal mucosa bleeding times of healthy dogs and of dogs in various pathologic states, including thrombocytopenia, uremia, and von Willebrand's disease. Am J Vet Res 1987, 48:1337-1342.
2. Brooks M., Catalfamo J. Buccal mucosa bleeding time is prolonged in canine models of primary hemostatic disorders. Thromb Haemost 1993, 70:777-780.
3. Harrison P. The role of PFA-100 testing in the investigation and management of haemostatic defects in children and adults. Br J Haematol 2005, 130:3-10.
4. Burgess H.J., Woods J.P., Abrams-Ogg A.C.G., et al. Evaluation of laboratory methods to improve characterization of dogs with von Willebrand disease. Can J Vet Res 2009, 73:252-259.
5. Tarnow I., Kristensen A.T., Texel H., et al. Decreased platelet function in Cavalier King Charles Spaniels with mitral valve regurgitation. J Vet Intern Med 2003, 17:680-686.
6. Tarnow I., Kristensen A.T., Olsen L.H., et al. Dogs with heart diseases causing turbulent high-velocity blood flow have changes in platelet function and von Willebrand factor multimer distribution. J Vet Intern Med 2005, 19:515-522.
7. Moesgaard S.G., Sørensen T.M., Sterup A., et al. Changes in platelet function in Dachshunds with early stages of myxomatous mitral valve disease. Res Vet Sci 2009, 86:320-324.
8. Kol A., Borjesson D.L. Application of thrombelastography/thromboelastometry to veterinary medicine. Vet Clin Pathol 2010, 39:405-416.
9. Brooks M.B., Stokol T., Catalfamo J.L. Comparative hemostasis: animal models and new hemostasis tests. Clin Lab Med 2011, 31:139-159.
10. Dallap Schaer B.L., Wilkins P.A., Boston R., et al. Preliminary evaluation of hemostasis in neonatal foals using a viscoelastic coagulation and platelet function analyzer. J Vet Emerg Crit Care (San Antonio) 2009, 19:81-87.
11. Dallap Schaer B.L., Bentz A.I., Boston R.C., et al. Comparison of viscoelastic coagulation analysis and standard coagulation profiles in critically ill neonatal foals to outcome. J Vet Emerg Crit Care (San Antonio) 2009, 19:88-95.
12. McMichael M.A., Smith S.A. Viscoelastic coagulation testing: technology, applications, and limitations. Vet Clin Pathol 2011, 40:140-153.
13. Johansson P.I., Bochsen L., Andersen S., et al. Investigation of the effect of kaolin and tissue-factor-activated citrated whole blood, on clot-forming variables, as evaluated by thromboelastography. Transfusion 2008, 48(11):2377-2383.
14. Wiinberg B., Kristensen A.T. Thromboelastography in veterinary medicine. Semin Thromb Hemost 2010, 36:747-756.
15. Wiinberg B., Jensen A.L., Rojkjaer R., et al. Validation of human recombinant tissue factor-activated thromboelastography on citrated whole blood from clinically healthy dogs. Vet Clin Pathol 2005, 34:389-393.
16. Macieira S., Rivard G.E., Champagne J., et al. Glanzmann thrombasthenia in an Oldenbourg filly. Vet Clin Pathol 2007, 36:204-208.
17. Nielsen V.G., Geary B.T., Baird M.S. Evaluation of the contribution of platelets to clot strength by thromboelastography in rabbits: the role of tissue factor and cytochalasin D. Anesth Analg 2000, 91:35-39.
18. Theusinger O.M., Nurnberg J., Asmis L.M., et al. Rotation thromboelastometry (ROTEM) stability and reproducibility over time. Eur J Cardiothorac Surg 2010, 37:677-683.
19. Craft R.M., Chavez J.J., Bresee S.J., et al. A novel modification of the Thrombelastograph assay, isolating platelet function, correlates with optical platelet aggregation. J Lab Clin Med 2004, 143:301-309.
20. Bochsen L., Wiinberg B., Kjelgaard-Hansen M., et al. Evaluation of the TEG platelet mapping assay in blood donors. Thromb J 2007, 5:3.
21. Brainard B.M., Kleine S.A., Papich M.G., et al. Pharmacodynamic and pharmacokinetic evaluation of clopidogrel and the carboxylic acid metabolite SR 26334 in healthy dogs. Am J Vet Res 2010, 71:822-830.
22. Johnson G.J., Leis L.A., Rao G.H., et al. Arachidonate-induced platelet aggregation in the dog. Thromb Res 1979, 14:147-154.
23. Catalfamo J., Andersen T.T., Fenton J.W. Thrombin receptor-activating peptides unlike thrombin are insufficient for platelet activation in most species [abstract]. Thromb Haemost 1993, 69:1195.
24. van Werkum J.W., Kleibeuker M., Postma S., et al. A comparison between the Plateletworks-assay and light transmittance aggregometry for monitoring the inhibitory effects of clopidogrel. Int J Cardiol 2010, 140:123-126.
25. Hamel-Jolette A., Dunn M., Bedard C. Plateletworks: a screening assay for clopidogrel therapy monitoring in healthy cats. Can J Vet Res 2009, 73:73-76.
26. Can M.M., Tanboga I.H., Turkyilmaz E., et al. The risk of false results in the assessment of platelet function in the absence of antiplatelet medication: comparison of the PFA-100, multiplate electrical impedance aggregometry and verify now assays. Thromb Res 2010, 125:e132-e137.
27. Michelson A.D., Frelinger A.L., Furman M.I. Current options in platelet function testing. Am J Cardiol 2006, 98:4N-10N.
28. Shenkman B., Savion N., Dardik R., et al. Testing of platelet deposition on polystyrene surface under flow conditions by the cone and plate(let) analyzer: role of platelet activation, fibrinogen and von Willebrand factor. Thromb Res 2000, 99:353-361.
29. Sabino E.P., Erb H.N., Catalfamo J.L. Development of a collagen-binding activity assay as a screening test for type II von Willebrand disease in dogs. Am J Vet Res 2006, 67:242-249.
30. Brooks M., Dodds W.J., Raymond S.L. Epidemiologic features of von Willebrand's disease in Doberman pinschers, Scottish terriers, and Shetland sheepdogs: 260 cases (1984-1988). J Am Vet Med Assoc 1992, 200:1123-1127.
31. Raymond S.L., Jones D.W., Brooks M.B., et al. Clinical and laboratory features of a severe form of von Willebrand disease in Shetland sheepdogs. J Am Vet Med Assoc 1990, 197:1342-1346.
32. Johnson G.S., TM, Dodds W.J. Type II von Willebrand's disease in German shorthair pointers [abstract]. Vet Clin Pathol 1987, 16:7.
33. Brooks M., Raymond S., Catalfamo J. Severe, recessive von Willebrand's disease in German Wirehaired Pointers. J Am Vet Med Assoc 1996, 209:926-929.
34. Johnson G.S., Turrentine M.A., Tomlinson J.L. Detection of von Willebrand's disease in dogs with a rapid qualitative test, based on venom-coagglutinin-induced platelet agglutination. Vet Clin Pathol 1985, 14:11-18.
35. Read M.S., Smith S.V., Lamb M.A., et al. Role of botrocetin in platelet agglutination: formation of an activated complex of botrocetin and von Willebrand factor. Blood 1989, 74:1031-1035.
36. De Luca M., Facey D.A., Favaloro E.J., et al. Structure and function of the von Willebrand factor A1 domain: analysis with monoclonal antibodies reveals distinct binding sites involved in recognition of the platelet membrane glycoprotein Ib-IX-V complex and ristocetin-dependent activation. Blood 2000, 95:164-172.
37. Boudreaux M.K. Characteristics, diagnosis, and treatment of inherited platelet disorders in mammals. J Am Vet Med Assoc 2008, 233:1251-1259.
38. Boudreaux M.K., Kvam K., Dillon A.R., et al. Type I Glanzmann's thrombasthenia in a Great Pyrenees dog. Vet Pathol 1996, 33:503-511.
39. Livesey L., Christopherson P., Hammond A., et al. Platelet dysfunction (Glanzmann's thrombasthenia) in horses. J Vet Intern Med 2005, 19:917-919.
40. Boudreaux M.K., Catalfamo J.L. Molecular and genetic basis for thrombasthenic thrombopathia in otterhounds. Am J Vet Res 2001, 62(11):1797-1804.
41. Boudreaux M.K., Crager C., Dillon A.R., et al. Identification of an intrinsic platelet function defect in Spitz dogs. J Vet Intern Med 1994, 8:93-98.
42. Catalfamo J.L., Raymond S.L., White J.G., et al. Defective platelet-fibrinogen interaction in hereditary canine thrombopathia. Blood 1986, 67:1568-1577.
43. Gentry P.A., Cheryk L.A., Shanks R.D., et al. An inherited platelet function defect in a Simmental crossbred herd. Can J Vet Res 1997, 61:128-133.
44. Johnstone I.B., Lotz F. An inherited platelet function defect in Basset hounds. Can Vet J 1979, 20:211-215.
45. Boudreaux M.K., Dillon A.R., Ravis W.R., et al. Effects of treatment with aspirin or aspirin/dipyridamole combination in heartworm-negative, heartworm-infected, and embolized heartworm-infected dogs. Am J Vet Res 1991, 52(12):1992-1999.
46. Boudreaux M.K., Dillon A.R., Sartin E.A., et al. Effects of treatment with ticlopidine in heartworm-negative, heartworm-infected, and embolized heartworm-infected dogs. Am J Vet Res 1991, 52:2000-2006.
47. Johnstone I.B., Lotz F. An inherited platelet function defect in Basset hounds. Can Vet J 1979, 20:211-215.
48. Christopherson P.W., Insalaco T.A., van Santen V.L., et al. Characterization of the cDNA encoding alphaIIb and beta3 in normal horses and two horses with Glanzmann thrombasthenia. Vet Pathol 2006, 43:78-82.
49. Abrams C., Shattil S.J. Immunological detection of activated platelets in clinical disorders. Thromb Haemost 1991, 65:467-473.
50. Wills T.B., Wardrop K.J., Meyers K.M. Detection of activated platelets in canine blood by use of flow cytometry. Am J Vet Res 2006, 67:56-63.
51. Segura D., Monreal L., Perez-Pujol S., et al. Assessment of platelet function in horses: ultrastructure, flow cytometry, and perfusion techniques. J Vet Intern Med 2006, 20:581-588.
52. Boudreaux M.K., Panangala V.S., Bourne C. A platelet activation-specific monoclonal antibody that recognizes a receptor-induced binding site on canine fibrinogen. Vet Pathol 1996, 33:419-427.
53. Boudreaux M.K., Martin M. P2Y12 receptor gene mutation associated with postoperative hemorrhage in a Greater Swiss Mountain dog. Vet Clin Pathol 2011, 40:202-206.
54. Frelinger A.L., Cohen I., Plow E.F., et al. Selective inhibition of integrin function by antibodies specific for ligand-occupied receptor conformers. J Biol Chem 1990, 265:6346-6352.
55. Honda S., Tomiyama Y., Pelletier A.J., et al. Topography of ligand-induced binding sites, including a novel cation-sensitive epitope (AP5) at the amino terminus, of the human integrin beta 3 subunit. J Biol Chem 1995, 270:11947-11954.
56. Jennings L.K., White M.M., Mandrell T.D. Interspecies comparison of platelet aggregation, LIBS expression and clot retraction: observed differences in GPIIb-IIIa functional activity. Thromb Haemost 1995, 74:1551-1556.
57. Santoro M.L., Sano-Martins I.S. Platelet dysfunction during Bothrops jararaca snake envenomation in rabbits. Thromb Haemost 2004, 92:369-383.
58. von Zur Muhlen C., von Elverfeldt D., Choudhury R.P., et al. Functionalized magnetic resonance contrast agent selectively binds to glycoprotein IIb/IIIa on activated human platelets under flow conditions and is detectable at clinically relevant field strengths. Mol Imaging 2008, 7:59-67.
59. von zur Muhlen C., Peter K., Ali Z.A., et al. Visualization of activated platelets by targeted magnetic resonance imaging utilizing conformation-specific antibodies against glycoprotein IIb/IIIa. J Vasc Res 2009, 46:6-14.
60. Doré M., Hawkins H.K., Entman M.L., et al. Production of a monoclonal antibody against canine GMP-140 (P-selectin) and studies of its vascular distribution in canine tissues. Vet Pathol 1993, 30:213-222.
61. Gurney D., Lip G.Y., Blann A.D. A reliable plasma marker of platelet activation: does it exist?. Am J Hematol 2002, 70:139-144.
62. Shattil S.J., Hoxie J.A., Cunningham M., et al. Changes in the platelet membrane glycoprotein IIb.IIIa complex during platelet activation. J Biol Chem 1985, 260:11107-11114.
63. Tzima E., Walker J.H. Platelet annexin V: the ins and outs. Platelets 2000, 11:245-251.
64. Dachary-Prigent J., Pasquet J.M., Freyssinet J.M., et al. Calcium involvement in aminophospholipid exposure and microparticle formation during platelet activation: a study using Ca2+-ATPase inhibitors. Biochemistry 1995, 34:11625-11634.
65. Zwaal R.F., Comfurius P., Bevers E.M. Scott syndrome, a bleeding disorder caused by defective scrambling of membrane phospholipids. Biochim Biophys Acta 2004, 1636:119-128.
66. Brooks M.B., Catalfamo J.L., Brown H.A., et al. A hereditary bleeding disorder of dogs caused by a lack of platelet procoagulant activity. Blood 2002, 99:2434-2441.
67. Callan M.B., Bennett J.S., Phillips D.K., et al. Inherited platelet delta-storage pool disease in dogs causing severe bleeding: an animal model for a specific ADP deficiency. Thromb Haemost 1995, 74:949-953.